Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nalbuphine Hydrochloride

FDA-approved product (solution, intramuscular, intravenous, subcutaneous), marketed as Nalbuphine, Nalbuphine Hydrochloride, Nubain.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nalbuphine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Pain

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Morphinan derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nalbuphine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nalbuphine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Postoperative Pain Management on Patients Undergoing Lung Tumor Resection

    NCT06397807 · start 2024-05-31

    Registered record
    Registry ID
    NCT06397807
    Conditions
    Postoperative Pain; Lung Cancer; Lung Tumor
    Interventions
    Dinalbuphine sebacate; Analgesic injectables; Enteral analgesics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-05-31
    Completion
    2026-05-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain; Lung Cancer; Lung Tumor
    InterventionDinalbuphine sebacate; Analgesic injectables; Enteral analgesics
    PhaseNot recorded
    Registry statusUnknown

  • Cough Reduction in IPF With Nalbuphine ER

    NCT05964335 · start 2024-02-06

    Registered record
    Registry ID
    NCT05964335
    Conditions
    Idiopathic Pulmonary Fibrosis
    Interventions
    NAL ER; Placebo; NAL ER; NAL ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-02-06
    Completion
    2025-04-24
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Pulmonary Fibrosis
    InterventionNAL ER; Placebo; NAL ER; NAL ER
    PhasePhase 2
    Registry statusCompleted

  • An Integrated Artificial Intelligence Approach for Predicting Analgesic Time Based on Nalbuphine Versus Morphine as Adjuvants to Bupivacaine in Ultrasound-Guided Supraclavicular Block

    NCT07008443 · start 2024-01-01

    Registered record
    Registry ID
    NCT07008443
    Conditions
    Regional Anesthesia Block; Upper Limb Surgery
    Interventions
    Bupivacaine + saline; Bupivacaine + nalbuphine; Bupivacaine + morphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-01
    Completion
    2025-04-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRegional Anesthesia Block; Upper Limb Surgery
    InterventionBupivacaine + saline; Bupivacaine + nalbuphine; Bupivacaine + morphine
    PhasePhase 4
    Registry statusCompleted

  • Serratus Anterior Plane Block and Costotransverse Block for Analgesia Following Modified Radical Mastectomy Surgeries

    NCT06260397 · start 2023-12-28

    Registered record
    Registry ID
    NCT06260397
    Conditions
    Regional Anesthesia Morbidity
    Interventions
    serratus anterior plane block; costotransverse block; patient controlled analgesia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-12-28
    Completion
    2025-03-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRegional Anesthesia Morbidity
    Interventionserratus anterior plane block; costotransverse block; patient controlled analgesia
    PhaseNot applicable
    Registry statusUnknown

  • Postoperative Pain Management on Uvulopalatopharyngoplasty Patients

    NCT05825495 · start 2023-05-01

    Registered record
    Registry ID
    NCT05825495
    Conditions
    Pain, Postoperative; Obstructive Sleep Apnea-hypopnea Syndrome; Pain, Acute
    Interventions
    Dinalbuphine sebacate; Routine practice
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-05-01
    Completion
    2024-05-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative; Obstructive Sleep Apnea-hypopnea Syndrome; Pain, Acute
    InterventionDinalbuphine sebacate; Routine practice
    PhasePhase 4
    Registry statusUnknown

  • Supraclavicular Block vs Bier's Block for Forearm Trauma Surgery

    NCT07418086 · start 2023-04-01

    Registered record
    Registry ID
    NCT07418086
    Conditions
    Forearm Fractures
    Interventions
    Bier's Block (IVRA); Supraclavicular Block
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-01
    Completion
    2024-02-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionForearm Fractures
    InterventionBier's Block (IVRA); Supraclavicular Block
    PhaseNot applicable
    Registry statusCompleted

  • Analgesic Additives to Epidural Bupivacaine in Normal Labor

    NCT05746351 · start 2023-03

    Registered record
    Registry ID
    NCT05746351
    Conditions
    Labor Pain
    Interventions
    Dexmedetomidine; fentanyl; Nalbuphine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-03
    Completion
    2025-07
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLabor Pain
    InterventionDexmedetomidine; fentanyl; Nalbuphine
    PhaseNot applicable
    Registry statusUnknown

  • Observational Study on the Incorporation of Opioids and Their Metabolites Into Hair of Pediatric Patients

    NCT05740657 · start 2022-12-06

    Registered record
    Registry ID
    NCT05740657
    Conditions
    Opioid Use, Unspecified
    Interventions
    Fentanyl
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-12-06
    Completion
    2025-02-28
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use, Unspecified
    InterventionFentanyl
    PhaseNot recorded
    Registry statusCompleted

  • Comparison Between Two Different Doses of Nulbuphine _bupivacaine in TAP Block in Cancer Abdominal Surgeries

    NCT05090579 · start 2022-06-01

    Registered record
    Registry ID
    NCT05090579
    Conditions
    Pain, Postoperative
    Interventions
    Group I (BN10); Active Comparator:Group ll (BN20); Active Comparator:Group lll (B)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-06-01
    Completion
    2024-10-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionGroup I (BN10); Active Comparator:Group ll (BN20); Active Comparator:Group lll (B)
    PhaseNot applicable
    Registry statusUnknown

  • Effect of Caudal Nalbuphine on Postoperative Emergence Agitation in Pediatrics Undergoing Infra-umbilical Surgeries

    NCT05245721 · start 2022-03

    Registered record
    Registry ID
    NCT05245721
    Conditions
    Agitation, Emergence; Post Operative Pain
    Interventions
    Nalbuphine; Bupivacain
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-03
    Completion
    2023-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation, Emergence; Post Operative Pain
    InterventionNalbuphine; Bupivacain
    PhasePhase 1
    Registry statusUnknown

  • Postoperative Pain Management of Caesarean Section

    NCT05009771 · start 2022-02-23

    Registered record
    Registry ID
    NCT05009771
    Conditions
    Postoperative Pain; Caesarean Section; Analgesia
    Interventions
    Intravenous patient-control analgesia; Dinalbuphine sebacate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-02-23
    Completion
    2026-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain; Caesarean Section; Analgesia
    InterventionIntravenous patient-control analgesia; Dinalbuphine sebacate
    PhaseNot recorded
    Registry statusRecruiting

  • Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries

    NCT05041270 · start 2021-10-01

    Registered record
    Registry ID
    NCT05041270
    Conditions
    Lower Limb Surgeries
    Interventions
    normal saline; Dexmedetomidine; Nalbuphine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-10-01
    Completion
    2022-05-15
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Limb Surgeries
    Interventionnormal saline; Dexmedetomidine; Nalbuphine
    PhaseNot applicable
    Registry statusCompleted

  • Multimodal Postoperative Analgesia Following OSA Surgery

    NCT04483427 · start 2020-09-20

    Registered record
    Registry ID
    NCT04483427
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Nalbuphine, ketorolac, accufuser
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-09-20
    Completion
    2022-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionNalbuphine, ketorolac, accufuser
    PhaseNot applicable
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Conscious Sedation for Cataract Operations Under Topical Anaesthesia

    NCT03933280 · start 2019-07-01

    Registered record
    Registry ID
    NCT03933280
    Conditions
    Conscious Sedation
    Interventions
    Nalbuphine; Propofol; Dexmedetomidine; Benoxinate Hydrochloride 0.4% Eye Drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-01
    Completion
    2021-01-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConscious Sedation
    InterventionNalbuphine; Propofol; Dexmedetomidine; Benoxinate Hydrochloride 0.4% Eye Drops
    PhasePhase 2
    Registry statusCompleted